No Data
No Data
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
83% intracranial objective response rate (iORR) with Bria-IMT in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC resistant
BriaCell Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/24/2024 1185.44% HC Wainwright & Co. → $18 Reiterates Buy → Buy 12/28/2023 1185.44% HC Wainwright & Co.
This BriaCell Therapeutics Insider Increased Their Holding By 55% Last Year
H.C. Wainwright Maintains BriaCell Therapeutics(BCTX.US) With Buy Rating, Maintains Target Price $18
H.C. Wainwright analyst Emily Bodnar maintains $BriaCell Therapeutics(BCTX.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 3
Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing
Marc Lustig, 10% Owner, Director, on May 14, 2024, executed a purchase for 902,935 shares in Briacell Therapeutics (BCTX) for $2,000,001. Following the Form 4 filing with the SEC, Lustig has control o
BriaCell Therapeutics Secures $5M in Funding
No Data